{"id":32946,"date":"2025-05-07T11:32:43","date_gmt":"2025-05-07T03:32:43","guid":{"rendered":"https:\/\/flcube.com\/?p=32946"},"modified":"2025-05-07T11:32:44","modified_gmt":"2025-05-07T03:32:44","slug":"endocell-secures-rmb-200-million-in-financing-to-advance-islet-regeneration-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32946","title":{"rendered":"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology"},"content":{"rendered":"\n

EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company’s first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.<\/p>\n\n\n\n

Financing Rounds and Participants<\/strong>
The Series A funding was co-led by Shanghai Technology Venture Capital and Grand Neobay Ceyuan Fund, while the Pre-Series A+ round was led by Leo Group, with contributions from Panlin Capital and others.<\/p>\n\n\n\n

Pipeline and Facility Development<\/strong>
EndoCell is focused on the in vitro reconstruction of human tissues and organs, specifically developing regenerative islets for transplantation to treat diabetes. The company has established a 4000 square meter “Organ and Tissue Reconstruction Center” in Shanghai Lingang New City. This facility includes the world’s first fully A-grade fully enclosed GMP production line for regenerating pancreatic islets, positioning EndoCell at the forefront of regenerative medicine.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series…<\/p>\n","protected":false},"author":1,"featured_media":32948,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,4053,20],"class_list":["post-32946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-endocell-biotech","tag-finance"],"yoast_head":"\nEndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company's first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology\" \/>\n<meta property=\"og:description\" content=\"EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company's first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-07T03:32:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-07T03:32:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology\",\"datePublished\":\"2025-05-07T03:32:43+00:00\",\"dateModified\":\"2025-05-07T03:32:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946\"},\"wordCount\":184,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0705.webp\",\"keywords\":[\"Cell-therapy\",\"EndoCell Biotech\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32946#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32946\",\"name\":\"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0705.webp\",\"datePublished\":\"2025-05-07T03:32:43+00:00\",\"dateModified\":\"2025-05-07T03:32:44+00:00\",\"description\":\"EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company's first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32946\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0705.webp\",\"width\":1080,\"height\":608,\"caption\":\"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology - Insight, China's Pharmaceutical Industry","description":"EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company's first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32946","og_locale":"en_US","og_type":"article","og_title":"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology","og_description":"EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company's first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.","og_url":"https:\/\/flcube.com\/?p=32946","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-07T03:32:43+00:00","article_modified_time":"2025-05-07T03:32:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology","datePublished":"2025-05-07T03:32:43+00:00","dateModified":"2025-05-07T03:32:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32946"},"wordCount":184,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0705.webp","keywords":["Cell-therapy","EndoCell Biotech","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32946#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32946","url":"https:\/\/flcube.com\/?p=32946","name":"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32946#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0705.webp","datePublished":"2025-05-07T03:32:43+00:00","dateModified":"2025-05-07T03:32:44+00:00","description":"EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company's first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32946"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32946#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0705.webp","width":1080,"height":608,"caption":"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0705.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32946"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32946\/revisions"}],"predecessor-version":[{"id":32949,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32946\/revisions\/32949"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32948"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}